Who
Olivier Loeillot
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Repligen.
In numbers
- Trades disclosed
- 56
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $13.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Oct 2023
- Last trade
- 5 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 6 Oct 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $238K1,333 at $178.75 | filing |
| 5 Oct 2026filed 6 Oct 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code M | $651K4,202 at $154.96 | filing |
| 5 Oct 2026filed 6 Oct 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $798K4,202 at $190.00 | filing |
| 5 Oct 2026filed 6 Oct 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,202 at $0.00 | filing |
| 2 Oct 2026filed 5 Oct 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $227K1,248 at $181.70 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code M | $1.3M8,404 at $154.96 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $1.6M8,404 at $190.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code M | $706K4,542 at $155.38 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,404 at $0.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,542 at $0.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $863K4,542 at $190.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,404 at $0.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,542 at $0.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code M | $1.3M8,404 at $154.96 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $1.6M8,404 at $190.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code M | $706K4,542 at $155.38 | filing |
| 24 Sep 2026filed 25 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $863K4,542 at $190.00 | filing |
| 21 Sep 2026filed 22 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code M | $769K5,426 at $141.79 | filing |
| 21 Sep 2026filed 22 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $977K5,426 at $180.00 | filing |
| 21 Sep 2026filed 22 Sep 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,426 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.